UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 219

Sortiert nach

S7.3 - Enabling Asia-inclusive global drug development through quantitative and translational science

Drug metabolism and pharmacokinetics, 2020, Vol.35 (1), p.S13-S13

Venkatakrishnan, Karthik

2020

Link zum Volltext

Verfügbarkeit prüfen

Machine Learning in Modeling Disease Trajectory and Treatment Outcomes: An Emerging Enabler for Model‐Informed Precision Medicine

Clinical pharmacology and therapeutics, 2024-04, Vol.115 (4), p.720-726

2024

Link zum Volltext

Verfügbarkeit prüfen

Physiologically‐Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study

Clinical pharmacology and therapeutics, 2021-01, Vol.109 (1), p.51-54

2021

Link zum Volltext

Verfügbarkeit prüfen

Reverse Translation: The Art of Cyclical Learning

Clinical pharmacology and therapeutics, 2018-02, Vol.103 (2), p.152-159

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

Clinical pharmacokinetics, 2019-04, Vol.58 (4), p.431-449

2019

Link zum Volltext

Verfügbarkeit prüfen

Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions

Drug metabolism and disposition, 2007-02, Vol.35 (2), p.246

2007

Link zum Volltext

Verfügbarkeit prüfen

Population PK and Exposure–Response Relationships for the Antibody–Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study

Clinical pharmacology and therapeutics, 2018-11, Vol.104 (5), p.989-999

2018

Link zum Volltext

Verfügbarkeit prüfen

Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug–drug interaction studies

Clinical and translational science, 2022-09, Vol.15 (9), p.2075-2095

2022

Link zum Volltext

Verfügbarkeit prüfen

How resilient were we in 2021? Results of a LinkedIn Survey including biomedical and pharmaceutical professionals using the Benatti Resiliency Model

Clinical and translational science, 2022-10, Vol.15 (10), p.2355-2365

2022

Link zum Volltext

Verfügbarkeit prüfen

Effect of severe renal impairment on the pharmacokinetics of brigatinib

Investigational new drugs, 2021-10, Vol.39 (5), p.1306-1314

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

Clinical cancer research, 2012-09, Vol.18 (17), p.4775-4784

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

Investigational new drugs, 2021-04, Vol.39 (2), p.488-498

2021

Link zum Volltext

Verfügbarkeit prüfen

Switching from body surface area‐based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis

British journal of clinical pharmacology, 2015-05, Vol.79 (5), p.789-800

2015

Link zum Volltext

Verfügbarkeit prüfen

Model‐informed assessment of ethnic sensitivity and dosage justification for Asian populations in the global clinical development and use of cladribine tablets

Clinical and translational science, 2022-02, Vol.15 (2), p.297-308

2022

Link zum Volltext

Verfügbarkeit prüfen

The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions

The Journal of pharmacology and experimental therapeutics, 2006-01, Vol.316 (1), p.336

2006

Link zum Volltext

Verfügbarkeit prüfen

Variable or variate? A conundrum in pharmacometrics exposure–response models

CPT: pharmacometrics and systems pharmacology, 2023-02, Vol.12 (2), p.144-147

2023

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach

CPT: pharmacometrics and systems pharmacology, 2024-04, Vol.13 (4), p.624-637

2024

Link zum Volltext

Verfügbarkeit prüfen

Risk assessment of drug–drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach

Clinical and translational science, 2022-12, Vol.15 (12), p.2838-2843

2022

Link zum Volltext

Verfügbarkeit prüfen

Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma

Clinical and translational science, 2024-03, Vol.17 (3), p.e13730-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude

Drug metabolism and disposition, 2005-06, Vol.33 (6), p.845

2005

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients

CPT: pharmacometrics and systems pharmacology, 2022-08, Vol.11 (8), p.1085-1099

2022

Link zum Volltext

Verfügbarkeit prüfen

Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab

CPT: pharmacometrics and systems pharmacology, 2022-03, Vol.11 (3), p.333-347

2022

Link zum Volltext

Verfügbarkeit prüfen

Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models

CPT: pharmacometrics and systems pharmacology, 2022-10, Vol.11 (10), p.1371-1381

2022

Link zum Volltext

Verfügbarkeit prüfen

Model‐based meta‐analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus

CPT: pharmacometrics and systems pharmacology, 2024-02, Vol.13 (2), p.281-295

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 219

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(216)
Mit Volltextzugriff
(178)

Publikationsform

Artikel
(214)
Tagungsberichte
(5)

Sprache

Englisch
(219)
Japanisch
(31)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

S7.3 - Enabling Asia-inclusive global drug development through quantitative and translational science

Machine Learning in Modeling Disease Trajectory and Treatment Outcomes: An Emerging Enabler for Model‐Informed Precision Medicine

Physiologically‐Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study

Reverse Translation: The Art of Cyclical Learning

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions

Population PK and Exposure–Response Relationships for the Antibody–Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study

Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug–drug interaction studies

How resilient were we in 2021? Results of a LinkedIn Survey including biomedical and pharmaceutical professionals using the Benatti Resiliency Model

Effect of severe renal impairment on the pharmacokinetics of brigatinib

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

Switching from body surface area‐based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis

Model‐informed assessment of ethnic sensitivity and dosage justification for Asian populations in the global clinical development and use of cladribine tablets

The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions

Variable or variate? A conundrum in pharmacometrics exposure–response models

Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

Risk assessment of drug–drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach

Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma

In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude

Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients

Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab

Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models

Model‐based meta‐analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus

Suchergebnisse filtern